Saniona AB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.11.22	Saniona publishes its interim report for the third quarter of 2022 (GlobeNewswire)
03.11.22	Saniona’s anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies (GlobeNewswire)
30.09.22	Saniona extends runway and amends loan agreement with Formue Nord (GlobeNewswire)
25.08.22	Saniona publishes its interim report for the second quarter of 2022 (GlobeNewswire)
18.08.22	Bulletin from the Saniona AB extraordinary general meeting on August 18, 2022 (GlobeNewswire)
16.08.22	Saniona progresses its Kv7 epilepsy program into Lead Optimization (GlobeNewswire)
05.08.22	Saniona provides update on outstanding option programs (GlobeNewswire)
15.07.22	Notice of extraordinary general meeting in Saniona AB (GlobeNewswire)
06.07.22	Saniona CEO Thomas Feldthus and board member Carl Johan Sundberg purchase Saniona shares in the open market (GlobeNewswire)
30.06.22	Saniona reports positive top line results from the SAN711 Phase 1 Clinical Trial (GlobeNewswire)
24.06.22	Saniona’s preclinical candidate SAN903 shows robust dampening of fibrosis in Chronic Kidney Disease model (GlobeNewswire)
25.05.22	Bulletin from the Saniona AB annual shareholders’ meeting on May 25, 2022 (GlobeNewswire)
25.05.22	Saniona publishes its interim report for the first quarter of 2022 (GlobeNewswire)
23.05.22	Saniona´s Clinical Trial in Hypothalamic Obesity Published in Scientific Journal (GlobeNewswire)
20.05.22	Saniona provides update on ongoing review of tesofensine in Mexico (GlobeNewswire)
30.04.22	Saniona publishes its Annual Report for 2021 (GlobeNewswire)
27.04.22	Saniona Changes Date of Annual Report for 2021 (GlobeNewswire)
25.04.22	Notice of Saniona AB annual shareholders’ meeting (GlobeNewswire)
25.04.22	Saniona Announces Refocused Strategy on Ion Channel R&D and Restructuring of Board of Directors and Executive Management Team (GlobeNewswire)
29.03.22	Saniona Announces Strategic Program Prioritization and Restructuring to Streamline Operational Costs (GlobeNewswire)
24.03.22	Saniona Initiates Positron Emission Tomography (PET) Stage of SAN711 Phase 1 Clinical Trial (GlobeNewswire)
21.03.22	Saniona ion channel research collaboration with Boehringer Ingelheim advances to next stage (GlobeNewswire)
01.03.22	Saniona to participate in multiple upcoming investor conferences (GlobeNewswire)
24.02.22	Saniona publishes its year-end report for 2021 (GlobeNewswire)
10.02.22	Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	311.20	2.37 %	K V
Part Grp Hldg	1’257.00	2.36 %	K V
Novartis	93.53	2.15 %	K V
Geberit	524.40	1.51 %	K V
Roche Hldg G	254.80	1.47 %	K V
Sika	230.50	0.66 %	K V
UBS Group	28.21	0.25 %	K V
Nestle	76.04	0.11 %	K V
Swisscom	506.00	0.10 %	K V
Kuehne+Nagel Int	208.10	0.05 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Saniona AB

Aktien Top/Flop

Meistgelesene Nachrichten